Theranostics centre

See what you treat, and treat what you see.

Discuss your project

Diagnose, treat, verify

Theranostic care pairs a diagnostic radiotracer with a therapeutic radionuclide that share the same target, so a cancer is imaged and confirmed before it is treated. We support the full chain each programme needs: isotope supply, radiochemistry, imaging and radiation protection.

  1. Diagnostic tracer

    A low-dose imaging isotope, such as Ga-68.

  2. Find the target

    PET shows where the tumours are.

  3. Therapeutic dose

    The same molecule carries Lu-177.

  4. Verify

    A follow-up scan checks the response.

Theranostics in practice

How it works, and where it is used today.

What is theranostics?

Video · 1:53

Rahim’s story

Video · 0:57
  • Targeted radiotracers

    A targeting molecule binds a marker on cancer cells. For diagnosis it carries an imageable isotope; for treatment, the same molecule carries a therapeutic one, sparing healthy cells.

  • A proven, expanding toolkit

    Radioactive iodine has treated thyroid cancer for over 80 years. Lu-177 and Ac-225 have extended the approach to prostate cancer and other solid tumours.

  • Prostate cancer

    177Lu-PSMA supports imaging and therapy for metastatic castration-resistant prostate cancer; 225Ac-PSMA is used when other treatments have not worked.

  • Neuroendocrine tumours

    68Ga-DOTATATE and 68Ga-DOTATOC locate neuroendocrine tumours on PET, guiding targeted radionuclide therapy.

Other solutions

All solutions

Planning a theranostics programme?

Tell us where your project stands, from a first idea to an existing facility that needs equipment or support.